Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirtazapine versus olanzapine for prevention of chemotherapy-induced nausea and vomiting in breast cancer
IRCT20100127003210N19Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in chemotherapy-induced nausea and vomiting (CINV) comparing Triple standard of care + mirtazapine with Triple standard of care + olanzapine (2 arms). Primary endpoints: Severity of nausea and Severity of vomiting. Started Jan 2020; status: completed.
02
Drugs
mirtazapineolanzapine
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on IRCT20100127003210N19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20100127003210N19.